ATE341545T1 - Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase - Google Patents

Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Info

Publication number
ATE341545T1
ATE341545T1 AT02745602T AT02745602T ATE341545T1 AT E341545 T1 ATE341545 T1 AT E341545T1 AT 02745602 T AT02745602 T AT 02745602T AT 02745602 T AT02745602 T AT 02745602T AT E341545 T1 ATE341545 T1 AT E341545T1
Authority
AT
Austria
Prior art keywords
quinoline derivatives
tyrosine kinase
kinase inhibitors
containment
medicament
Prior art date
Application number
AT02745602T
Other languages
English (en)
Inventor
Laurent Francois And Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE341545T1 publication Critical patent/ATE341545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02745602T 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase ATE341545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401895 2001-07-16
EP01403123 2001-12-05

Publications (1)

Publication Number Publication Date
ATE341545T1 true ATE341545T1 (de) 2006-10-15

Family

ID=26077248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745602T ATE341545T1 (de) 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Country Status (8)

Country Link
US (1) US7501516B2 (de)
EP (1) EP1409481B1 (de)
JP (1) JP4326328B2 (de)
AT (1) ATE341545T1 (de)
DE (1) DE60215178T2 (de)
ES (1) ES2272737T3 (de)
HK (1) HK1063185A1 (de)
WO (1) WO2003008409A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK2142003A3 (en) 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
US6939866B2 (en) 2000-10-13 2005-09-06 Astrazeneca Ab Quinazoline derivatives
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
WO2003047584A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE429230T1 (de) 2002-07-09 2009-05-15 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
JP4593464B2 (ja) 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
WO2004069249A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
JP4936897B2 (ja) * 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
JPWO2005080392A1 (ja) 2004-02-19 2007-08-02 武田薬品工業株式会社 ピラゾロキノロン誘導体およびその用途
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
CA2654583C (en) * 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
PE20090595A1 (es) 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2639407T3 (es) * 2010-06-09 2017-10-26 Tianjin Hemay Oncology Pharmaceutical Co., Ltd. Derivados de cianoquinolina
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
US11427559B2 (en) 2018-02-20 2022-08-30 Teligene Ltd. Substituted quinolines useful as kinase inhibitors
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
JP2001503756A (ja) 1996-11-06 2001-03-21 ダーウィン・ディスカバリー・リミテッド キノリン類およびこれらの治療的使用
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
AU763618B2 (en) * 1999-02-10 2003-07-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
WO2001012227A1 (en) 1999-08-12 2001-02-22 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK2142003A3 (en) 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
US6939866B2 (en) 2000-10-13 2005-09-06 Astrazeneca Ab Quinazoline derivatives
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
ES2272737T3 (es) 2007-05-01
JP2004536860A (ja) 2004-12-09
HK1063185A1 (en) 2004-12-17
US20050009867A1 (en) 2005-01-13
DE60215178T2 (de) 2007-08-23
WO2003008409A1 (en) 2003-01-30
EP1409481A1 (de) 2004-04-21
EP1409481B1 (de) 2006-10-04
JP4326328B2 (ja) 2009-09-02
US7501516B2 (en) 2009-03-10
DE60215178D1 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
ATE353888T1 (de) Chinazolinderivate
MY129809A (en) Quinazoline derivatives
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
NO20061415L (no) Kinazolinderivater
DE60229046D1 (de) Chinazolin derivate
SE0104140D0 (sv) Novel Compounds
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SE0301700D0 (sv) Novel compounds
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
GB0124933D0 (en) Chemical compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties